Emerging Agents in BCG-Unresponsive NMIBC
A urologist discusses treatments in the pipeline that can further improve the therapeutic landscape in BCG-unresponsive NMIBC.
EP: 1.Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)
EP: 2.Treating Patients With High-Risk BCG-Unresponsive NMIBC
EP: 3.SunRISe-1: TAR-200 and Cetrelimab in Patients With High-Risk NMIBC
EP: 4.Ongoing Research in BCG-Unresponsive NMIBC
EP: 5.What Are the Advantages of TAR-200 in BCG-Unresponsive NMIBC?
EP: 6.Emerging Agents in BCG-Unresponsive NMIBC
EP: 7.Optimizing Patient Selection and Treatment Sequencing in BCG-Unresponsive NMIBC
This is a video synopsis/summary of an Investigator Perspectives featuring Neal Shore, MD, FACS.
Shore emphasizes the exciting developments in bladder cancer, including multiple new treatment approaches. Beyond the therapies already discussed, he highlights promising viral gene vectors like CG0070 to stimulate antitumor immunity when given intravesically.
For muscle invasive bladder cancer, efforts to spare the bladder are progressing with novel additions like intravesical devices or immunotherapy to enhance efficacy. The combination of enfortumab vedotin and pembrolizumab produced notable results for first-line metastatic disease in the phase 3 EV-302 trial, supporting study of this regimen in other settings like neoadjuvant therapy.
Finally, for non–muscle invasive disease, combining emerging strategies with BCG could synergize effects. Across settings from BCG-unresponsive high-risk non–muscle invasive bladder cancer to frontline metastatic disease, Dr Shore conveys excitement for the rapid evolution in bladder cancer research and care.
Video synopsis is AI generated and reviewed by Urology Times® editorial staff.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
